IN THE CLAIMS

Please cancel claims 4, 7, 11, 13-14, and 17-23 without prejudice or disclaimer. Please add the following new claims 24-27.

This listing of the claims replaces all prior versions of the claims in the application.

- 1. (Currently amended) An isolated polypeptide comprising selected from the group consisting of:
- a) a[[n]] polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:19. SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40, SEQ ID NO:42-48, SEQ ID NO:50-55.
- b) <u>a polypeptide comprising</u> a naturally occurring amino acid sequence having at least 90% sequence identity to [[an]] <u>the</u> amino acid sequence selected from the group consisting of <u>SEQ ID NO:19</u>, SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40,SEQ ID NO:42-48, SEQ ID NO:50-55,
- c) a biologically active fragment of <u>a polypeptide comprising</u> [[an]] <u>the</u> amino acid sequence selected from the group consisting of <u>SEQ ID NO:19, and</u> <u>SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40, SEQ ID NO:42-48, SEQ ID NO:50-55, or</u>
- d) an immunogenic fragment of [[an]] the amino acid sequence selected from the group consisting of SEQ ID NO:19. SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40, SEQ ID NO:42-48, SEQ ID NO:50-55.
- 2. (Currently amended) An isolated polypeptide of claim 1, having [[an]] the amino acid sequence selected from the group consisting of <u>SEQ ID NO:19</u>. <u>SEQ ID NO:17</u>, <u>SEQ ID NO:35-55</u>, <u>SEQ ID NO:7-14</u>, <u>SEQ ID NO:16-31</u>, <u>SEQ ID NO:33-34</u>, <u>SEQ ID NO:36-40</u>, <u>SEQ ID NO:42-48</u>, <u>SEQ ID NO:50-55</u>.
 - 3. (Original) An isolated polynucleotide encoding a polypeptide of claim 1.

- 4. (Canceled).
- 5. (Original) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
 - 6. (Original) A cell transformed with a recombinant polynucleotide of claim 5.
 - 7. (Canceled).
 - 8. (Original) A method for producing a polypeptide of claim 1, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
 - b) recovering the polypeptide so expressed.
 - 9. (Original) An isolated antibody which specifically binds to a polypeptide of claim 1.
- 10. (Currently amended) An isolated polynucleotide comprising selected from the group consisting of:
- a) a polynucleotide <u>comprising the polynucleotide</u> sequence selected from the group consisting of SEQ ID NO:56-110 <u>SEQ ID NO:74</u>,
- b) <u>a polynucleotide comprising</u> a naturally occurring polynucleotide sequence having at least 90% sequence identity to [[a]] <u>the</u> polynucleotide sequence selected from the group consisting of SEQ ID NO:56-110 <u>SEQ ID NO:74</u>,
 - c) a polynucleotide sequence complementary to a), or
 - d) a polynucleotide sequence complementary to b)[[.]], and
 - e) an RNA equivalent of a)-d).

119786 4 09/889,616

11. (Canceled).

12. (Original) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

- a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

13.-14. (Canceled).

- 15. (Original) A pharmaceutical composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
- 16. (Original) A method of treating a disease or condition associated with decreased expression of functional NuABP, comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 15.

17.-23. (Canceled).

24. (New) A microarray wherein at least one element of the microarray is a polynucleotide of claim 3.

119786 5 09/889,616

25. (New) A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 24 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.
- 26. (New) An isolated polynucleotide consisting of at least 60 contiguous nucleotides of a polynucleotide of claim 10.
- 27. (New) A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 3, the method comprising:
 - exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
 - b) detecting altered expression of the target polynucleotide, and
 - c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.